Abstract: The present invention relates generally to the field of biomarkers. The biomarker identified in the present invention is phenol. For example, the present invention relates to the use of phenol as a biomarker for detecting and/or quantifying mood disorder, improvements of the mood disorder status and/or the resulting emotional reaction of a subject. Embodiments of the resent invention relate to a method of detecting and/or quantifying mood disorder, improvements of the mood disorder status and/or the resulting emotional reaction of a subject, comprising determining the level of phenol in a body sample obtained from a subject to be tested, and comparing the subject's phenol level to a predetermined reference value, wherein a decreased phenol level in the sample compared to the predetermined reference value indicates an improvement of the mood disorder status and/or the resulting emotional reaction of the subject.

Abstract: The present invention relates generally to the field of biomarkers. The biomarker identified in the present invention is 2-methylbutyrate. For example, the present invention relates to the use of 2-methylbutyrate as a biomarker for detecting and/or quantifying mood disorder and improvements of the mood disorder status and/or the resulting emotional reaction of a subject. Embodiments of the resent invention relate to a method of detecting and/or quantifying mood disorders, improvements of the mood disorder status and/or the resulting emotional reaction of a subject, comprising determining the level of 2-methylbutyrate in a body sample obtained from a subject to be tested, and comparing the subject's 2-methylbutyrate level to a predetermined reference value, wherein an increased 2-methylbutyrate level in the sample compared to the predetermined reference value indicates an improvement of the mood disorder status and/or the resulting emotional reaction of the subject.

Abstract: The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal.

Abstract: The present invention provides a nutritional composition for use in glucose management. The nutritional composition comprises one or more amino acids, or combinations thereof, selected from the group consisting of: hydroxyproline, proline, ornithine and alpha-aminobutyric acid, that can be particularly beneficial for children or adolescents for use in glucose management.

Abstract: The present invention provides a nutritional composition for use in a weight loss dietary intervention or maintenance of weight, particularly following a dietary intervention, preferably a low caloric diet intervention. The nutritional composition comprises one or more amino acids, or combinations thereof, selected from the group consisting of: proline, histidine, glycine, and/or hydroxyproline, that can be used to help the weight loss in obese subjects that are resistant to weight loss by caloric restricted dietary interventions alone. In addition, the nutritional composition of the invention can be used to help maintain the weight loss, particularly after dietary intervention.

Abstract: The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal.

Abstract: The invention relates to compositions and methods using a combination of at least one histidine or derivative thereof, at least one glycine or derivative thereof, and at least one additional agent selected from N-acetyl-cysteine, lysine, or arginine. An aspect of the invention is a method of promoting healthy fat metabolism and metabolic health in children at risk of developing insulin resistance and diabetes, promoting healthy lipolysis and use of fatty acid in metabolism, promoting healthy fat and adipocyte metabolism during puberty and adolescence, treating or preventing oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, or a condition associated with a reduced level of glutathione, by administering an effective amount of a combination of at least one glycine or derivative thereof, and lysine.

Abstract: The present invention generally relates to a method for predicting high blood level glucose in biofluid of a subject. Methods of improving glucose level management in an adolescent subject are also provided. The present invention generally relates to a method for predicting high HOMA-IR in biofluid of a subject. Methods of improving glucose and insulin metabolism in a child, or an adolescent subject or a young adult are also provided.

Abstract: The present invention relates to a method for determining a level of fat-free body mass (FFM) in a paediatric subject comprising determining a level of phenylacetylglutamine (PAG) in a sample obtained from the subject.

Abstract: The present invention generally relates to a method for predicting high blood level glucose in biofluid of a subject. Methods of improving glucose level management in an adolescent subject are also provided.

Abstract: The present invention relates to a method for determining a level of fat-free body mass (FFM) in a paediatric subject comprising determining a level of phenylacetylglutamine (PAG) in a sample obtained from the subject.

Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be trimethylamine-N-oxide.

Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to trimethylamine as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.

Abstract: The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof.

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort including centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-ODE as biomarker.

Abstract: A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin D, alpha-linolenic acid, and vitamin K in a ratio of vitamin K1:vitamin K2 between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 cal of the nutritional composition. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin D, alpha-linolenic acid, and vitamin K in a ratio of vitamin K1:vitamin K2 between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 cal of the nutritional composition. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin K in a ratio of vitamin K1:vitamin K2 being between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 kcal of the nutritional composition, vitamin D and alpha-linolenic acid. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.

Abstract: The present invention relates generally to the field of nutrition and health, particular, the present invention relates to alpha-keto-isovalerate as a biomarker urine of the efficacy of prebiotics for the prevention of diet induced weight gain.